Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. develops clinical-stage immune-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. News about APVO centers on mipletamig, its CD123 x CD3 program for acute myeloid leukemia, including clinical data, safety observations, orphan drug designation for AML, and combination studies with venetoclax and azacitidine.
Company updates also cover pipeline expansion into bispecific, multispecific and trispecific candidates, solid-tumor work such as ALG.APV-527, conference presentations, financing arrangements, operating results, shareholder voting matters, and governance changes tied to Aptevo’s public-company structure.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aptevo Therapeutics reported significant 2022 milestones and financial results, achieving a net income of $8.0 million ($1.57 per share) compared to a net loss of $28.5 million in 2021. The company announced progress in clinical trials for APVO436 in Acute Myeloid Leukemia (AML), which demonstrated substantial clinical activity and a favorable safety profile. The Phase 2 trial for APVO436 is set for late 2023. Additionally, ALG.APV-527, for solid tumors, began patient dosing in February 2023. Aptevo also filed a provisional patent for APVO711 targeting various solid malignancies. As of December 31, 2022, cash and equivalents totaled $22.6 million.
Aptevo Therapeutics (NASDAQ:APVO) announced the completion of a transaction that raised $9.6 million in non-dilutive funding by selling future IXINITY payments and milestones to XOMA Corporation. The company plans to use part of the proceeds to fully repay its debt, leaving it with approximately $26 million in cash and a debt-free status. Additional potential milestones related to IXINITY could yield up to $5.8 million through regulatory approvals and sales performance. This move extends Aptevo's cash runway beyond 12 months and reinforces its commitment to shareholders amid challenging market conditions.